title: Disseminated neuroblastomas under 1 year of age: cell biology and prognosis.
abstract: Tumor specimens of 203 infants with neuroblastomas of different clinical stages-registered in successive multicenter clinical trials of the German Society of Pediatric Oncology-could be examined for N-myc amplification, chromosome 1-ploidy and-structure, CD44 std. expression (in tumor tissue, and also in patient's sera). Eighty-seven (= 43%) of these infants had a non-localized, disseminated neuroblastoma, mainly involving sympathetic nerve tissue, lymph nodes, liver, skin, bone marrow and bones (46 patients were classified into the 4 group, 41 patients in the true 4 group). If the clinical classification between stage 4 and stage 4s was neglected, then 17 of these infants (= 20%) had N-myc amplification (4-64 copies) with 16 already dead. Seven of 9 examined patients with true stage 4- had chromosome 1p aberrations (with N-myc amplification in 5), and among the dead there were 2 with CD44 negative expression. In another series, serum CD44 std. was measured by ELISA, and the highest (significantly different) Kruskal-Wallis mean rank values (147.8) were found in infants (n = 6) with stage 4s compared to the low mean-rank-value of 71.9 in patients with stage 4 (n = 65). Stage 1-3 patients (n = 42) had values of 99.8-88.6. Thus, infants with disseminated neuroblastomas, showing non-diploidy, normal chromosome 1p structure, non-N-myc amplification and high CD44 std. expression in tumor tissue, and also high CD44 std. values in serum, will have the highest chance of survival due to tumor-non-progression. On the other hand, N-myc amplification in the tumor cells was found to be characteristic for stage 4s neuroblastoma patients with tumor progression (n = 6). Therefore, 4s neuroblastoma-patients with N-myc amplified tumors should be aggressively treated like true stage 4 tumor patients.
authors.affiliation: Department of Pediatrics, Hematology and Oncology, University of Giessen, Germany.
authors.forename: F
authors.initials: F
authors.lastname: Lampert
authors.forename: H
authors.initials: H
authors.lastname: Christiansen
authors.forename: F
authors.initials: F
authors.lastname: Berner
authors.forename: H J
authors.initials: HJ
authors.lastname: Terpe
authors.forename: F
authors.initials: F
authors.lastname: Berthold
mesh_terms: D004797:Enzyme-Linked Immunosorbent Assay; D005784:Gene Amplification; D018628:Gene Dosage; D016259:Genes, myc / Q000502:physiology; D006801:Humans; D007223:Infant; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality*; D011379:Prognosis; D016019:Survival Analysis